An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer

The goal of this observational research is to assess the real-world clinical utility of PYLARIFY PET through evaluation of long-term outcomes for prostate cancer patients who are eligible for a PSMA/PET scan. Participants will be enrolled at their physician's office at the time of referral for PYLARIFY PET and will be followed for up to 5 years. Data concerning their prostate cancer diagnostics and treatment will be collected at 6-month intervals.

NCT Number	NCT05712473
Lead Sponsor	Specialty Networks Research. Collaborators: Lantheus Medical Imaging
Conditions	Prostate Cancer
Enrollment	500 participants
Start Date	2023-02
Primary Completion	2028-12 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2023-02-03